CMV DNA is rarely detected in healthy blood donors using validated PCR assays

Transfusion

Volumn 43, Issue 3, 2003, Pages 314-321

  Roback, John D ^a   Drew, W Lawrence ^b   Laycock, Megan E ^b   Todd, Deborah ^b   Hillyer, Christopher D ^b   Busch, Michael P ^b  

^a EMORY UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; DNA SEQUENCE; ENZYME IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; SEROLOGY; VIRUS DETECTION; VIRUS INFECTION;

ANTIBODIES, VIRAL; BLOOD DONORS; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; DNA, VIRAL; FALSE NEGATIVE REACTIONS; HUMANS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 0037344273     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00312.x     Document Type: Article

References (43)

1. Yeager AS, Grumet FC, Hafleigh EB, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981;98:281-7.
2. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-10.
3. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246-50.
4. Miller WJ, McCullough J, Balfour HH, Jr., et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991;7:227-34.
5. Winston DJ, Ho WG, Howell CL, et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 1980;93:671-5.
6. Hersman J, Meyers JD, Thomas ED, et al. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 1982;96:149-52.
7. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-88.
8. Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion 1990;30:762-3.
9. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14 (+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999;93:394-8.
10. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A 1998;95:3937-42.
11. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119-26.
12. Soderberg-Naucler C, Fish KN, Nelson JA. Interferongamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997;100:3154-63.
13. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-603.
14. Hillyer CD, Emmens RK, Zago-Novaretti, et al. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion 1994;34:929-34.
15. Roback JD, Bray RA, Hillyer CD. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: implications for transfusion transmission of infections. Transfusion 2000;40:500-6.
16. Verdonck LF, de Graan-Hentzen YC, Dekker AW, et al. Cytomegalovirus seronegative platelets and leukocytepoor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 1987;2:73-8.
17. Gilbert GL, Hayes K, Hudson IL, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1989;8649:1228-31.
18. de Graan-Hentzen YC, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989;29:757-60.
19. De Witte T, Schattenberg A, Van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990;50:964-8.
20. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection (Letter). Blood 1996;87:4910.
21. Stanier P, Taylor DL, Kitchen AD, et al. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors [Comments]. BMJ 1989;299:897-8.
22. Bevan IS, Daw RA, Day PJ, et al. Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population. Br J Haematol 1991;78:94-9.
23. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, et al. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991;72:2059-64.
24. Larsson S, Soderberg-Naucler C, Wang FZ, et al. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion 1998;38:271-8.
25. Jiwa NM, Van Gemert GW, Raap AK, et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 1989;48:72-6.
26. Cassol SA, Poon MC, Pal R, et al. Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. Application to the early diagnosis of CMV infection in marrow transplant recipients. J Clin Invest 1989;83:1109-15.
27. Rowley AH, Wolinsky SM, Sambol SP, et al. Rapid detection of cytomegalovirus DNA and RNA in blood of renal transplant patients by in vitro enzymatic amplification. Transplantation 1991;51:1028-33.
28. Bitsch A, Kirchner H, Dupke R, et al. Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction [Comments]. Transfusion 1992;32:612-7.
29. Smith KL, Kulski JK, Cobain T, et al. Detection of cytomegalovirus in blood donors by the polymerase chain reaction. Transfusion 1993;33:497-503.
30. Nolte FS, Emmens RK, Thurmond C, et al. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 1995;33:1263-6.
31. Revello MG, Zavattoni M, Sarasini A, et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998;177:1170-5.
32. Tegtmeier GE, Henderson SE, Blosser JK, et al. CMV DNA in plasma of seroconverting and anti-CMV seroprevalent blood donors (Abstract). Transfusion 1999;39(Suppl 10):116s.
33. Roback JD, Hillyer CD, Drew WL, et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 2001;41:1249-57.
34. Lee TH, Sakahara NS, Fiebig EW, et al. Quantitation of white cell subpopulations by polymerase chain reaction using frozen whole-blood samples. Viral Activation Transfusion Study. Transfusion 1998;38:262-70.
35. Lee TH, Stromberg RR, Heitman J, et al. Quantitation of residual white cells in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA. Transfusion 1994;34:986-94.
36. Long CM, Drew L, Miner R, et al. Detection of cytomegalovirus in plasma and cerebrospinal fluid specimens from human immunodeficiency virus-infected patients by the AMPLICOR CMV test. J Clin Microbiol 1998;36:2434-8.
37. Drew WL, Tegtmeier G, Alter HJ, et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003;43:309-313.
38. Zanghellini F, Boppana SB, Emery VC, et al. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999;180:702-7.
39. Zhu J, Shearer GM, Marincola FM, et al. Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: existence of a Th1-type dominant response. Int Immunol 2001;13:785-90.
40. Dumont LJ, Luka J, VandenBroeke T, et al. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 2001;97:3640-7.
41. Preiksaitis JK, Brown L, McKenzie, M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988;157:523-9.
42. Hillyer CD, Snydman DR, Berkman EM. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products. Transfusion 1990;30:659-66.
43. Wilhelm JA, Matter L, Schopfer K. The risk of transmitting cytomegalovirus to patients receiving blood transfusions. J Infect Dis 1986;154:169-71.